2024 International Congress » Therapy in Movement Disorders: Gene and Cell-Based Therapies

Meeting: 2024 International Congress

Development of an AAV-mediated artificial miRNA targeting human alpha-synuclein (α-syn) as a potential gene therapy for Synucleinopathies

S. Basu, V. Singh, N. Gattone, J. Li, B. Wicks, X. Huang, E. Fabyanic, S. Wang, M. Li, X. Qian, G. Rivera-Pena, C. Li, Z. Yu, P. Raman, E. Kostuk, MG. Biferi, E. Ramsburg (Philadelphia, USA)

IGF2 Induce Neuroprotection in PD Preclinical Models by Modulation of Immune Response.

FG. Grünenwald, MC. Cisternas, DS. Sepulveda, TH. Huerta, CJ. Jerez, RP. Pacheco, RLV. Vidal (Santiago, Chile)

Motor and Non-Motor Outcomes of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

C. Henchcliffe, H. Sarva, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (Orange, USA)

PARKIN gene replacement by AAV-mediated gene delivery as a therapeutic modality for PARKIN-deficient early-onset familial Parkinson’s disease

N. Gattone, AJ. Gilsrud, S. Basu, T. Demarest, B. Wicks, E. Kostuk, D. Narendra, MG. Biferi, E. Ramsburg (Philadelphia, USA)

Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (New York, USA)

« View all sessions from the 2024 International Congress.